Pipeline

Endeavor BioMedicines white Icon

Endeavor BioMedicines’ Pipeline

Program

Preclinical

Phase 1

Phase 2

Phase 3

Taladegib

IPF

Hedgehog Pathway Inhibitor

Pipeline Ellipse
Pipeline Ellipse
Pipeline Ellipse

PC

P1

P2

P3

Endeavor BioMedicines blue logo

Phase 2a Clinical Trial Results

At the American Thoracic Society 2024 International Conference, Endeavor BioMedicines announced results from a completed Phase 2a clinical trial that demonstrate our lead investigational candidate, taladegib (ENV-101), improved lung function, increased total lung capacity and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF).

Learn More
Scientist Conducting Experiments in a Laboratory